Company / Total Assets
Inmune Bio, Inc. Total Assets History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$32.4M
FY2025
5-year range
$32.4M / $99.9M
FY2021-FY2025
Trend
-18.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has declined for 4 consecutive years, from $100M in FY2021 to $32M in FY2025.
Based on SEC 10-K filings.
$32M in FY2025 with a 5-year CAGR of -4.5%.
Declined from $57M to $32M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -26.6%
- 5-Year CAGR
- -4.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Inmune Bio, Inc.'s total assets has declined for 4 consecutive years.
- 5-year CAGR of -4.5%, indicating a declining trend.
- In FY2025, total assets decreased 18.2% year-over-year.
- Peak total assets was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.4M | -18.2% |
| FY2024 | $39.6M | -30.6% |
| FY2023 | $57.0M | -30.3% |
| FY2022 | $81.8M | -18.2% |
| FY2021 | $99.9M | +145.8% |
| FY2020 | $40.7M | +134.1% |
| FY2018 | $17.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026